Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.48 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.43 |
| ▸ | ACLY | P53396 | 3/20 | 0.42 |
| ▸ | STK39 | Q9UEW8 | 4/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341987 | 0.84 | EGFR (0.46) | EGFRERBB2TRPV1ALDH1A1ABCC1 | |
| SCHEMBL4351073 | 0.83 | HTT (0.40) | EGFRERBB2ALOX15MAPK1TRPV1 | |
| SCHEMBL4351338 | 0.83 | ALOX15 (0.59) | ALOX15MAPK1LMNAHTTNPSR1 | |
| SCHEMBL4355801 | 0.83 | EGFR (0.48) | EGFRERBB2STK39ALDH1A1LMNA | |
| SCHEMBL4351304 | 0.81 | ABCC1 (0.39) | EGFRERBB2ALOX15TRPV1ALDH1A1 | |
| SCHEMBL4352857 | 0.77 | MEN1 (0.59) | ACLYALOX15MAPK1ALDH1A1LMNA | |
| SCHEMBL4342070 | 0.76 | EGFR (0.43) | EGFRERBB2ACLYTRPV1ALDH1A1 | |
| SCHEMBL4355478 | 0.76 | EGFR (0.43) | EGFRERBB2HSPA5ACLYSTK39 | |
| SCHEMBL4349798 | 0.75 | ALDH1A1 (0.46) | EGFRERBB2ALDH1A1LMNAHTT | |
| SCHEMBL4351495 | 0.75 | ABCC1 (0.39) | EGFRERBB2TRPV1ALDH1A1ABCC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | JERINI AG (DE) | 2011-03-17 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | JERINI AG (DE) | 2007-03-08 | — | — | US | claimed |
| EP-2100876-A2 | New compounds for the inhibition of rotamases and use thereof | Jerini AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065760-A1 | COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF | NR1I3, NR1D1, NR1D2 | EGFR 1661/4885ERBB2 1297/4885HSPA5 4499/4885 |
| US-20070054904-A1 | Phenol derivatives and their use as rotamase inhibitors | NR1I3, NR1D1, NR1D2 | EGFR 1635/4885ERBB2 1020/4885HSPA5 4585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.